Lymphocyte-derived interleukin-17A adds another brick in the wall of inflammation-induced breast carcinogenesis

Jérémy Bastid (1) , Nathalie Bonnefoy (2) , Jean-François Eliaou (2, 3) , Armand Bensussan (4, 5)

1 OREGA Biotech
2 IRCM - U896 Inserm - UM1 - Institut de recherche en cancérologie de Montpellier
3 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
4 Inserm UMR-S 976
5 SU - Sorbonne Université

We have previously reported that a subset of breast tumors are infiltrated with IL-17A-producing tumor-associated lymphocytes and that IL-17A cytokine is principally associated with estrogen receptor negative (ER-) and triple negative, basal-like tumors. We established that IL-17A producing lymphocytes induced cancer cell proliferation, chemoresistance, and invasion, indicating that IL-17A is a potential therapeutic target for breast malignancies.

Domaines: Sciences du Vivant [q-bio]

Jérémy Bastid, Nathalie Bonnefoy, Jean-François Eliaou, Armand Bensussan. Lymphocyte-derived interleukin-17A adds another brick in the wall of inflammation-induced breast carcinogenesis. OncoImmunology, 2014, 3, pp.e28273. ⟨10.4161/onci.28273⟩. ⟨hal-02110853⟩